Zyter Acquires Casenet, LLC – Enhances Case Management, Disease Management, and Utilization Management Capabilities

February 2, 2021

Zyter reports Casenet provides a comprehensive suite of enterprise care management software products for commercial, Medicaid, Medicare, TPA, provider/ACO and specialty provider organizations. These population health management products enable healthcare payers and providers to improve care coordination as well as the quality and delivery of care.

Currently Casenet’s TruCare products manage approximately 11% of the United States population.  Recognized as a market leader by KLAS, a leading research firm, Casenet products have been named Best in KLAS three years in a row for Software & Services (2017 and 2018) and Care Management Solutions (2019).

“Casenet is a care management market and technology leader,” said Sanjay Govil, founder and CEO of Zyter, Inc.  “This strategic acquisition adds capabilities that complement our expanding portfolio of digital health products for providers, patients and especially payers.”

With this acquisition, Casenet TruCare products will be enhanced with Zyter’s clinical collaboration, remote patient monitoring, and interoperability products, helping organizations improve operations and patient outcomes while reducing the overall cost of care.

While Zyter already offers a number of payer products, the acquisition of Casenet adds more advanced capabilities in the areas of care management, disease management, utilization management and analytics.  For example, Casenet’s TruCare Analytics application uses machine learning to model risk, identify populations, and provide segmentation so payers can make better, more informed care management decisions.

“This acquisition improves our ability to provide a 360-degree view of each member, making it easier for payers and providers to identify opportunities to coordinate and enhance care,” said Govil.

Zyter will maintain the Casenet brand and TruCare care management products will continue to be marketed and sold as stand-alone offerings and in combination with Zyter.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”